@madamswer could almost have fed you those lines...
and like the dutiful scribe that you are, you could have posted them with zero understanding of his abysmal track record on predicting MSB's financial demise.
Regardless, the truth is you have no serious insight into Oaktree's probable and most likely course of action especially in this space of stem cell therapies. BA ANU is not great for financial acumen, let alone navigating the world of biotechnology finance, is it?
Ann: Mesoblast Type A Meeting with FDA, page-401
-
- There are more pages in this discussion • 174 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 75212 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |